Boostrix GlaxoSmithKline Biologicals - Treatment for Prevention of Diphtheria, Tetanus & Pertussis in AdolescentsBoostrix is indicated as a single dose active booster immunization against tetanus, diphtheria, and pertussis in individuals 10 through 18 years of age, thereby adding a pertussis component to the routine tetanus/diphtheria booster currently administered to teens.
Posted: May 2005
- FDA approves Boostrix to prevent tetanus, diphtheria, and pertussis in older people - July 11, 2011
- FDA Approves GlaxoSmithKline Tetanus, Diphtheria, Whooping Cough Vaccine, Boostrix, for Adults - December 13, 2008
- GlaxoSmithKline Receives Unanimous Favorable Recommendation by FDA Advisory Committee for Boostrix - March 15, 2005
- GlaxoSmithKline Submits Biologics License Application for FDA Approval of Boostrix - July 7, 2004
More News Resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our Newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.